Intended for US Audiences Only

Important Safety Information
Prescribing Information
Visit Healthcare Professional Site

About IXINITY
Real Patient Ixperiences
Starting IXINITY
Supporting Patients
The IXINITY IXperience™
In The Community

Free Trial
Connect With Us

Search

Free Trial
Connect With Us

Connect With a Hemophilia Territory Manager
Free Trial of IXINITY
Talking With Your Healthcare Provider
How To Use IXINITY

Starting IXINITY

Taking the first step

Whether you are starting on IXINITY^® for the first time or have some questions, use these helpful links or contact us for more information.

FREE trial offer
Talking with your healthcare provider

Find out about the IXINITY Savings Program
How to Use IXINITY

Connect With a Hemophilia Territory Manager
Connect With Us
Email Us
Contact an IXperience Concierge

Medexus Pharma
Privacy Policy
Terms of Use
Site Map

Call 1-855-IXINITY (1-855-494-6489) to speak with your IXperience™ Concierge for more information on IXINITY.

Medexus Pharma, Inc., Chicago, IL 60606

IXINITY [coagulation factor IX (recombinant)] and any and all Medexus Pharma, Inc. brand, product, service and feature names, logos, and slogans are trademarks or registered trademarks of Medexus Pharma, Inc. in the United States and/or other countries.

©2021 Medexus Pharma, Inc.
All rights reserved. MP-IX-0334

^*Median (IQR) Annualized Spontaneous Bleeding Rate (AsBR) of 0
achieved with twice-weekly prophylaxis IQR (range: 0-1.22) (N=61)¹

Discover the proven bleed protection of IXINITY^® »

Reference: 1. IXINITY [coagulation factor IX (recombinant)] prescribing information. Chicago, IL: Medexus Pharma, Inc.; November 2022.

INDICATIONS AND IMPORTANT SAFETY INFORMATION

Expand

What is IXINITY?

IXINITY [coagulation factor IX (recombinant)] is a medicine used to replace clotting factor (factor IX) that is missing in adults and children at least 12 years of age with hemophilia B. Hemophilia B is also called congenital factor IX deficiency or Christmas disease. Hemophilia B is an inherited bleeding disorder that prevents clotting. Your healthcare provider may give you IXINITY for routine prophylaxis, for on demand treatment to control bleeding episodes or when you have surgery.

IXINITY is not indicated for induction of immune tolerance in patients with hemophilia B.

IMPORTANT SAFETY INFORMATION for IXINITY

You should not use IXINITY if you are allergic to hamsters or any ingredients in IXINITY.
You should tell your healthcare provider if you have or have had medical problems, take any medicines, including prescription and non-prescription medicines, such as over-the-counter medicines, supplements, or herbal remedies, have any allergies, including allergies to hamsters, are nursing, are pregnant or planning to become pregnant, or have been told that you have inhibitors to factor IX.
You can experience an allergic reaction to IXINITY. Contact your healthcare provider or get emergency treatment right away if you develop a rash or hives, itching, tightness of the throat, chest pain, or tightness, difficulty breathing, lightheadedness, dizziness, nausea, or fainting.
Your body may form inhibitors to IXINITY. An inhibitor is part of the body's defense system. If you develop inhibitors, it may prevent IXINITY from working properly. Consult with your healthcare provider to make sure you are carefully monitored with blood tests for development of inhibitors to IXINITY.
If you have risk factors for developing blood clots, the use of IXINITY may increase the risk of abnormal blood clots.
Call your healthcare provider right away about any side effects that bother you or do not go away, or if your bleeding does not stop after taking IXINITY.
The most common side effect that was reported with IXINITY during clinical trials was headache.
These are not all the side effects possible with IXINITY. You can ask your healthcare provider for information that is written for healthcare professionals.

For more information about IXINITY, please see full Prescribing Information, including Important Patient Information.

You are encouraged to report adverse events related to Medexus Pharma products by calling 1-844-859-6675. If you prefer, you may contact the Food and Drug Administration directly. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.